Inoviq Ltd (AU:IIQ)
ASX:IIQ
Holding AU:IIQ?
Track your performance easily

Inoviq Ltd (IIQ) Share Price & Analysis

0 Followers

IIQ Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

5.88%94.12%
― Other Institutional Investors
94.12% Public Companies and
Individual Investors

IIQ FAQ

What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.43 and its highest was AU$0.92 in the past 12 months.
    What is Inoviq Ltd’s market cap?
    Currently, no data Available
    When is Inoviq Ltd’s upcoming earnings report date?
    Inoviq Ltd’s upcoming earnings report date is Feb 21, 2025 which is in 103 days.
      How were Inoviq Ltd’s earnings last quarter?
      Inoviq Ltd released its earnings results on Aug 21, 2024. The company reported -AU$0.037 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.037.
        Is Inoviq Ltd overvalued?
        According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Inoviq Ltd pay dividends?
          Inoviq Ltd does not currently pay dividends.
          What is Inoviq Ltd’s EPS estimate?
          Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Inoviq Ltd have?
          Inoviq Ltd has 111,526,700 shares outstanding.
            What happened to Inoviq Ltd’s price movement after its last earnings report?
            Inoviq Ltd reported an EPS of -AU$0.037 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Inoviq Ltd?
              Currently, no hedge funds are holding shares in AU:IIQ
              ---

              Inoviq Ltd Stock Smart Score

              Company Description

              Inoviq Ltd

              Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Cyclopharm Limited
              LBT Innovations Limited
              IDT Australia Limited
              Race Oncology Ltd.
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis